Literature DB >> 21411089

Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment.

Timothy P Murphy1, Rajoo Dhangana, Michael J Pencina, Abdul M Zafar, Ralph B D'Agostino.   

Abstract

BACKGROUND: There is a strong positive association between Framingham Risk Scores (FRS) in a population and incidence of hard coronary heart disease (hCHD) events. Under current Adult Treatment Panel III guidelines, individuals with FRS that indicate ≥20% 10-year risk of hCHD are recommended to receive intensive medical risk factor modification. We sought to assess the performance of FRS as a predictive tool when used as in current guidelines.
METHODS: A retrospective analysis of two prospective cohort studies, the Atherosclerosis Risk in Communities (ARIC) study, and Cardiovascular Health Study (CHS), including 11,436 and 2569 participants, respectively, without known cardiovascular disease or diabetes at baseline, with available FRS variables were analyzed. The FRS was computed according to standard algorithm. The main outcome was hCHD event defined as MI or coronary death. Using Receiver Operating Characteristics (ROC) curves, sensitivity, specificity, accuracy and other test performance characteristics were determined at various 10-year risk thresholds. ROC curves were plotted.
RESULTS: During 10-year follow-up, 822 hCHD events occurred. FRS was significantly associated with hCHD with an AUC of 0.77 and 0.68 for ARIC and CHS, respectively (p-values <0.0001). However, at standard "high risk" cut-off (≥20%), the sensitivity of FRS was only 13% and 25%, respectively and Youden's Index was only 0.10 and 0.15. Lowering the 10-year risk threshold to >5% improved prediction sensitivity to 75% and 83%, with specificity of 66% and 40%, respectively.
CONCLUSION: When used dichotomously as in current guidelines, sensitivity of the conventional 20% 10-year risk threshold for subsequent hCHD events is quite low. Since the 20% 10-year risk threshold for intensive medical risk factor therapy is on the steep part of the ROC curve, lowering the threshold results in substantial increases in sensitivity with much smaller losses in specificity, even to a threshold as low as 5%.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411089     DOI: 10.1016/j.atherosclerosis.2011.02.020

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

Review 1.  Cardiovascular risk assessment: a global perspective.

Authors:  Dong Zhao; Jing Liu; Wuxiang Xie; Yue Qi
Journal:  Nat Rev Cardiol       Date:  2015-03-10       Impact factor: 32.419

2.  Yield of screening for coronary artery calcium in early middle-age adults based on the 10-year Framingham Risk Score: the CARDIA study.

Authors:  Tochi M Okwuosa; Philip Greenland; Hongyan Ning; Kiang Liu; Donald M Lloyd-Jones
Journal:  JACC Cardiovasc Imaging       Date:  2012-09

3.  Cardiovascular Risk in HIV-Infected and Uninfected Postmenopausal Minority Women: Use of the Framingham Risk Score.

Authors:  Yamnia I Cortés; Nancy Reame; Cosmina Zeana; Haomiao Jia; David C Ferris; Elizabeth Shane; Michael T Yin
Journal:  J Womens Health (Larchmt)       Date:  2016-09-09       Impact factor: 2.681

Review 4.  Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.

Authors:  Nicolas Vuilleumier; Fabrizio Montecucco; Oliver Hartley
Journal:  World J Cardiol       Date:  2014-05-26

5.  Inflammatory cardiovascular risk biomarkers: update on novelties and limitations.

Authors:  Fabrizio Montecucco; François Mach; Aldo Pende; Thomas H Schindler; Rafaela F da Silva; Nicolas Vuilleumier
Journal:  Mediators Inflamm       Date:  2012-06-04       Impact factor: 4.711

6.  Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*.

Authors:  Brigitte M Sondermeijer; Annemieke Bakker; Amalia Halliani; Maurice W J de Ronde; Arnoud A Marquart; Anke J Tijsen; Ties A Mulders; Maayke G M Kok; Suzanne Battjes; Steffi Maiwald; Suthesh Sivapalaratnam; Mieke D Trip; Perry D Moerland; Joost C M Meijers; Esther E Creemers; Sara-Joan Pinto-Sietsma
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

7.  Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals.

Authors:  Alessandra Quercioli; Fabrizio Montecucco; Katia Galan; Osman Ratib; Pascale Roux-Lombard; Sabrina Pagano; François Mach; Thomas H Schindler; Nicolas Vuilleumier
Journal:  Mediators Inflamm       Date:  2012-11-07       Impact factor: 4.711

Review 8.  Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives.

Authors:  P C Teixeira; P Cutler; N Vuilleumier
Journal:  Clin Dev Immunol       Date:  2012-11-20

9.  Combination of high ankle-brachial index and hard coronary heart disease Framingham Risk Score in predicting the risk of ischemic stroke in general population.

Authors:  Yinyin Zhang; Jie Chen; Kun Zhang; Tong Wang; Minyi Kong; Renhua Chen; Yu Liu; Jianping Chen; Zhiyu Wang; Jingfeng Wang; Hui Huang
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

10.  Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.

Authors:  Priscila Camillo Teixeira; Axel Ducret; Philippe Ferber; Hubert Gaertner; Oliver Hartley; Sabrina Pagano; Michelle Butterfield; Hanno Langen; Nicolas Vuilleumier; Paul Cutler
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.